biOasis Announces Voting Results for 2017 Annual Meeting

The Company welcomes new board members Dr. Nancy Stagliano, Dr. Deborah Rathjen and Dr. Maha Radhakrishnan

VANCOUVER, British Columbia–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI) today announced the voting results from its Annual General Meeting held on Sept. 21, 2017 in Vancouver, British Columbia. The total number of shares represented in person or by proxy at the meeting was 17,212,451, representing 33.45% of the total issued and outstanding biOasis shares.

All directors nominated by management were approved, including new members Nancy Stagliano, Ph.D., Deborah Rathjen, Ph.D., and Maha Radhakrishnan, M.D. as well as returning members Rob Hutchison (Chairman, founder and former chief executive officer), Mark Day, Ph.D. (CEO), Ron Erickson and Michael Hutchison, QC. Messrs. Gubitz, Pearson and Fibiger were not nominated for re-election to the board at the AGM. The Company wishes to thank Messrs. Gubitz, Pearson and Fibiger for all of their efforts on behalf of the Company. As previously announced, Michael Hutchison will step down from the board in October and Rob Hutchison will retire from the company on Dec. 31, 2017.

In addition to the new board slate, the shareholders approved the option & restricted stock unit (RSU) plans.

Election of Directors

All seven (7) candidates nominated for election to the biOasis Board of Directors and listed in the Company’s Management Information Circular, dated Aug. 21, 2017, were elected by a majority of the shareholders present in person or represented by proxy at the meeting. The voting results are as follows:

Robin Hutchison       15,587,366 (91)       1,620,085 (9)
Mark Day, Ph.D.       17,207,451 (99.9)       0 (0)
Mahalakshmi Radhakrishnan, M.D.       17,146,951 (99.6)       60,500 (<0.01)
Deborah Ann Rathjen, Ph.D.       17,147,451 (99.6)       60,000 (<0.01)
Nancy E. Stagliano, Ph.D.       17,207,451 (99.9)       0 (0)
Ronald P. Erickson       16,016,866 (93)       1,190,585 (7)
J. Michael Hutchison, QC       15,617,366 (91)       1,590,085 (9)

Compensation Committee

Nancy Stagliano, Ph.D. (chair), Deborah Rathjen, Ph.D. and Mark Day, Ph.D. have been appointed to the Compensation, Governance and Nominating Committee.

Audit Committee

Deborah Rathjen, Ph.D. (chair), Mahalakshmi Radakrishnan, M.D. and Ronald Erickson have been appointed members of the Audit Committee.

Appointment of Auditors

biOasis also announced today that its shareholders have approved the re-appointment of Manning Elliott LLP, Accountants and Business Advisors as the Auditor of biOasis to hold office until the next annual meeting of shareholders.

About biOasis

biOasis Technologies Inc. is a biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB). The delivery of therapeutics across the BBB represents the single greatest challenge in treating neurological disorders. The company is developing and commercializing the xB3 platform, biOasis’ proprietary blood-brain barrier delivery technology, to address unmet medical needs in the treatment of central nervous system diseases and disorders. The company maintains headquarters in Vancouver, Canada with offices in Connecticut, United States. BiOasis trades on the OTCQB under the symbol “BIOAF” and on the TSX Venture Exchange under the symbol “BTI.” For more information about the company please visit

Forward-Looking Statements

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe,” “may,” “plan,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at . Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

On Behalf of the Board of Directors
Dr. Mark Day
President & Chief Executive Officer
biOasis Technologies, Inc.

“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.”


biOasis Technologies, Inc.
Catherine London, +1 917-763-2709
[email protected]
Graeme Dick, +1 403-561-8989
[email protected]